NewMed Medical

What NewMed Medical does

Shanghai NewMed Medical Technology Co., Ltd. (上海纽脉医疗科技股份有限公司), founded in March 2015 by Dr. Yu Qifeng, is a Chinese Class III implantable medical device company focused on transcatheter structural heart disease interventions. The company's product portfolio covers transcatheter heart valve replacement and repair systems (TAVR, TMVR, TMVr) and interventional ventricular assist devices (pVAD), supported by a complete accessory platform including balloon dilation catheters (Prizballoon, Prizballoon Pro), guide wires (Prizorbit, Prizorbit Pro), expandable sheath kits (Prizsheath), and inflation devices (SourcePump). Proprietary technology platforms span cobalt-chromium and nickel-titanium alloy processing, medical polymer materials, bovine pericardium anti-calcification tissue treatment, and large-balloon catheter engineering. Prizvalve, approved by NMPA in August 2024, is China's first domestically developed balloon-expandable TAVR system, with Prizvalve Pro approved in June 2025 as a second-generation upgrade.

NewMed Medical generates revenue through one-time hardware sales of Class III implantable devices to public tertiary hospitals in China via government medical device procurement and tender processes. The company deploys a sales-led, field-based enterprise go-to-market targeting major cardiac surgery and cardiology departments, with clinical adoption driven by KOL engagement through top-tier clinical trial sites (Zhongshan Hospital, Xijing Hospital, West China Hospital, Fuwai Hospital) and academic conference participation at venues such as China Valve, CSI, and CIMDR. A strategic commercial partnership with Xiangrikui Medical Technology provides additional channel support. The company operates through wholly-owned and majority-owned subsidiaries in Shanghai (HQ and R&D), Chengdu (subsidiary manufacturing and bovine pericardium processing), Beijing, and Jiaxing (Zhejiang, opened 2025).

The company maintains a strong IP and regulatory moat with 530+ patent applications, 295 granted patents, 5 products in the NMPA Innovation Medical Device Special Review Green Channel, and participation as the only device company in drafting industry standard YY/T 1787-2021. Cumulative disclosed funding exceeds USD 100M from a Series C in March 2021 led by OrbiMed, with subsidiary Huanqing Medical completing a separate Series A in November 2023. The addressable market is supported by a substantial China TAVR penetration gap (0.8% in China vs. 5% globally per Frost & Sullivan).

Name

NewMed Medical

Legal name

上海纽脉医疗科技股份有限公司

Website

https://newmed.cn

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

NewMed Medical is a Chinese Class III medical device company specializing in transcatheter heart valve replacement and repair systems (TAVR, TMVR, TMVr) and interventional ventricular assist devices, serving public tertiary hospitals across China with proprietary structural heart disease technology.

Ownership category

akta.pro rank

Product category

Cardiovascular Implantable Medical Devices (Structural Heart Disease)

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Structural heart disease devices
• Transcatheter heart valves
• Interventional cardiac devices
• Ventricular assist systems
• Implantable cardiovascular devices

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales (Hospital Procurement): NewMed Medical generates revenue through the sale of Class III implantable medical devices (transcatheter heart valves, balloon catheters, guidewires, introducer sheaths) to public hospitals via government procurement and tender processes. Revenue is primarily one-time transactional per device sold, with recurring revenue potential from consumables and accessories used in procedures.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

NewMed Medical develops, manufactures, and sells Class III implantable transcatheter heart valve replacement and repair systems and interventional ventricular assist devices for structural heart disease treatment. Core products include the Prizvalve® and Prizvalve Pro® balloon-expandable TAVR systems, Mi-thos® transcatheter mitral valve replacement (TMVR) system, Valveclip-M® transcatheter mitral valve repair (TMVr) device, and the 焕梅® interventional ventricular assist system (pVAD), supported by a comprehensive accessory system (balloon dilation catheters, guide wires, sheath kits, balloon inflation devices). Products are sold to public tertiary hospitals in China via government medical device procurement and tender processes.

Product overview

NewMed Medical (上海纽脉医疗科技股份有限公司) is a high-end medical device company specializing in transcatheter structural heart disease interventions. The company operates a dual-core product strategy combining transcatheter artificial heart valve systems and interventional ventricular assist systems. Core valve products include Prizvalve Pro® (second-generation balloon-expandable TAVR system) and Prizvalve® (first domestically manufactured balloon-expandable TAVR), Mi-thos® (transcatheter mitral valve replacement), Valveclip-M® (transcatheter mitral valve repair), and 焕梅® (interventional ventricular assist/pVAD). These are supported by a comprehensive accessory system portfolio covering balloon dilation catheters (Prizballoon®, Prizballoon Pro®), guide wires (Prizorbit®, Prizorbit Pro®), expandable and adjustable-bending sheath kits, and balloon inflation devices (SourcePump®). All products are developed, manufactured, and sold in-house, with subsidiaries in Shanghai, Chengdu, Beijing, and Jiaxing providing R&D and production capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• 纽脉奇点创新中心: Innovation center integrating government, industry, academia, research, medicine and investment for cross-disciplinary collaboration in advanced medical device development
• Prizvalve
• Prizvalve Pro
• Mi-thos
• Valveclip-M
• Prizballoon
• Prizballoon Pro
• Prizorbit
• Prizorbit Pro
• SourcePump
• Prizsheath
• 焕梅

Quantifiable outcome

• Prizvalve 1-year all-cause mortality rate of 2.5% in 120-patient clinical trial (mean age 74.7 years)
• +3 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, important and minor.

• Fudan University Affiliated Zhongshan Hospital (复旦大学附属中山医院)coreStrategic or Co-development PartnerLong-term clinical research partnership for Mi-thos TMVR and Prizvalve TAVR. Zhongshan Hospital led the first multi-center confirmatory clinical study for Mi-thos and was a key PI site for Prizvalve. Professor Wang Chunsheng and Professor Wei Lai serve as lead investigators. The hospital is a national leader in minimally invasive cardiac surgery.
• Air Force Military Medical University Xijing Hospital (空军军医大学西京医院)coreStrategic or Co-development PartnerKey clinical trial site for Prizvalve and Mi-thos. Professor Yang Jian's team pioneered multiple first-in-China structural heart disease interventions using NewMed devices. The hospital has performed over 500 TAVR procedures and 200+ other valvular interventions.
• Sichuan University West China Hospital (四川大学华西医院)coreStrategic or Co-development PartnerLead PI site for Prizvalve multi-center clinical trial. Professor Chen Mao's team led the clinical development of Prizvalve and has performed groundbreaking TMVR procedures. West China Hospital collaborated on the 13th Five-Year National Key R&D Program.
• Beihang University (北京航空航天大学)importantStrategic or Co-development PartnerJoint 'Implantable Medical Device Biomechanics Innovation Laboratory' established March 2023, focused on biomechanics research for implantable cardiovascular devices. Led by Professor Fan Yubo. Leverages university's basic research and talent resources for medical device development.
• Sichuan University (四川大学)importantStrategic or Co-development PartnerJoint 'Biomaterials & Medical Device Technology Innovation Laboratory' established for biomaterials research and medical device innovation collaboration.
• Zhejiang University (浙江大学)importantStrategic or Co-development PartnerJoint laboratory with Zhejiang University School of Medicine's Polymer Department for 'Medical Polymer Materials & Medical Device Technology.' Established December 2021, focused on polymer material research for medical devices.
• Xiangrikui Medical Technology (项日葵医疗科技)importantChannel Partner/ Reseller/ DistributorStrategic commercial partnership signed August 2022 for market expansion, academic promotion, business process optimization, and channel development in the structural heart disease field. Xiangrikui is a professional commercialization platform serving innovative medical device companies.
• Huanqing Medical Technology (上海焕擎医疗科技有限公司)importantStrategic or Co-development PartnerControlled subsidiary established 2022 focused on interventional ventricular assist device (pVAD) R&D and industrialization. Incubated through NewMed Qidian Innovation Center. Completed tens of millions RMB Series A financing in November 2023.
• Zhangjiang High-Tech 895 Startup Camp (张江高科895创业营)minorStrategic or Co-development PartnerNewMed Medical was an early-stage incubatee of Zhangjiang 895 Startup Camp (Season 1), receiving initial incubation support, angel investment from mentor Zhang Jie, and Pre-A round financing from Zhangke Lingyi Fund managed by mentor Yu Xiaoyong.
• Fuwai Cardiovascular Disease Hospital (中国医学科学院阜外医院)importantStrategic or Co-development PartnerCollaboration on structural heart disease interventions, including MitraClip clinical development discussions. Part of NewMed's network of top cardiac surgery KOLs.

Scale indicators14 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Venus MedTech (Hangzhou Venus MedTech): Hangzhou-based Chinese structural heart company and leading domestic TAVR player (VenusA-Valve, VenusP-Valve), now publicly listed. Direct competitor to NewMed in transcatheter aortic and tricuspid valve replacement, serving the same Chinese tertiary hospitals.
• MicroPort CardioFlow (微创心通): Shanghai-based TAVR subsidiary of MicroPort Scientific, with self-expanding TAVR (VitaFlow) approved in China. Direct China-headquartered competitor to NewMed in transcatheter aortic valve replacement; competing for the same procurement tenders.
• Peijia Medical (沛嘉医疗): Suzhou-based Chinese structural heart and neurovascular device maker with TAVR products ( TaurusOne ) in market. Directly competes with NewMed in China's TAVR and TMVR space, also publicly listed.
• Jenscare Scientific (健世科技): Ningbo-based Chinese structural heart company developing transcatheter tricuspid (LuX-Valve) and aortic valve replacement systems. A direct peer in China TAVR/TTVR space competing for hospital adoption and clinical sites.

Broad incumbents

• Edwards Lifesciences: Global incumbent and originator of transcatheter aortic valve replacement (Sapien, Sapien 3, Sapien X4). Sets the clinical and pricing benchmark globally and in China; imports balloon-expandable valves that compete with Prizvalve in premium Chinese accounts.
• Medtronic: Global structural heart incumbent with the Evolut self-expanding TAVR platform, the leading self-expanding TAVR globally. Competes with NewMed's balloon-expandable platform across Chinese centers where it is sold.
• Abbott: Global structural heart player with MitraClip, the dominant transcatheter edge-to-edge mitral repair device. Direct competing platform to NewMed's Valveclip-M TMVr system in mitral repair.
• Boston Scientific: Global structural heart player building Watchman, ACURATE neo2 TAVR, and other structural heart platforms. Broad incumbent with overlapping cardiology and structural heart capabilities relevant to NewMed's portfolio expansion.

Emerging players

• HighLife Medical: France-based TMVR company developing transcatheter mitral valve replacement technology. Emerging global peer whose TMVR approach overlaps with NewMed's Mi-thos, even though the two target different geographies.
• 4C Medical Technologies: US-based company developing transcatheter mitral valve replacement (AltaValve) targeting mitral regurgitation. Emerging global peer in TMVR space whose technology and clinical approach overlap with NewMed's Mi-thos development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries6 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NewMed Medical